voruciclib

Small moleculeexperimental

Clinical trial activity

5 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2008 (NCT00840190)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)[C@@H]1CO
Mol. weight
469.84 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • p1446a-05
  • p1446a-05
  • voruciclib
  • voruciclib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03547115Phase 1May 31, 2018MEI Pharma
NCT02117336Phase 1Jun 1, 2014Dartmouth University, Harvard University, Piramal
NCT01841463Phase 1Aug 1, 2013Melanoma Research Foundation Breakthrough Consortium, Piramal, University of California, San Francisco, University of Texas at Houston
NCT00772876Phase 1Dec 1, 2008British Columbia Cancer Agency, Piramal, University of Alberta, University of Calgary, University of Western Ontario
NCT00840190Phase 1Dec 1, 2008Piramal
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PiramalFor profit4412008
British Columbia Cancer AgencyAcademic/Hospital1012008
Dartmouth UniversityAcademic/Hospital1012014
Harvard UniversityAcademic/Hospital1012014
MEI PharmaFor profit1112018
Melanoma Research Foundation Breakthrough ConsortiumAcademic/Hospital1012013
University of AlbertaAcademic/Hospital1012008
University of CalgaryAcademic/Hospital1012008
University of California, San FranciscoAcademic/Hospital1012013
University of Texas at HoustonAcademic/Hospital1012013
University of Western OntarioAcademic/Hospital1012008
11 organizations
Page 1 / 1